Skip to content

CardioPulmonary resuscitation with Argon (CPAr) trial

Status
Not yet recruiting
Phases
Phase 2
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2024-516864-27-00
Acronym
IRFMN 7557/8154
Enrollment
120
Registered
2024-10-07
Start date
Unknown
Completion date
Unknown
Last updated
2025-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiac arrest

Brief summary

48 h Serum Neuron Specific Enolase (NSE) concentration for evaluation of Ar activity on neuronal preservation.

Detailed description

hs-cTnT plasma concentration for evaluation of Ar activity on myocardial preservation;, Brain imaging (MRI with DWI and DTI, in patients that remain comatose), for evaluation of Ar activity on neuronal preservation;, Multiorgan function (circulating biomarkers);, Survival and CPC score up to 6 months, for evaluation of functional outcome.

Interventions

DRUGOXYGEN
DRUGArgon/Oxygen mixture

Sponsors

Istituto Di Ricerche Farmacologiche Mario Negri
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
48 h Serum Neuron Specific Enolase (NSE) concentration for evaluation of Ar activity on neuronal preservation.

Secondary

MeasureTime frame
hs-cTnT plasma concentration for evaluation of Ar activity on myocardial preservation;, Brain imaging (MRI with DWI and DTI, in patients that remain comatose), for evaluation of Ar activity on neuronal preservation;, Multiorgan function (circulating biomarkers);, Survival and CPC score up to 6 months, for evaluation of functional outcome.

Countries

Italy

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026